[NH:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][CH:9]=2)[NH:4][CH2:3][CH2:2]1.[Cl:11][C:12]1[CH:36]=[CH:35][C:34]([Cl:37])=[CH:33][C:13]=1[O:14][C:15]1[CH:20]=[CH:19][N:18]=[CH:17][C:16]=1[C:21](N1C2C(=CC=CC=2)CCC1)=[O:22]>>[Cl:11][C:12]1[CH:36]=[CH:35][C:34]([Cl:37])=[CH:33][C:13]=1[O:14][C:15]1[CH:20]=[CH:19][N:18]=[CH:17][C:16]=1[C:21]([N:1]1[C:10]2[C:5](=[CH:6][CH:7]=[CH:8][CH:9]=2)[NH:4][CH2:3][CH2:2]1)=[O:22]The title compound was prepared in analogy to Example 1, from 1,2,3,4-tetrahydro-quinoxaline (commercially available; CAS RN 3476-89-9) and 4-(2,5-dichloro-phenoxy)-nicotinic acid (Example 1, intermediate). Light yellow foam (99%). MS (ESI): m/z=400.06 [M+H]+.